Lonza (LONN.SW) traded up 0.57 % during a 24 hours period ending at 09:56 PM Central Europe on Monday 26th. One Lonza stock can currently be bought for about CHF 634.8 on popular exchanges. Current supply of Lonza stocks is 69.8 mn. Lonza has a current market capitalization of CHF 44.1 bn and approximately CHF 96.2 mn worth of Lonza was traded on exchanges in the last 24 hours. Since last month end, Lonza has traded 10.84 % up. Simple moving average of last 200 days is at CHF 535.65. The highest price of past 52 weeks was recorded at CHF 636.2 on 10/23/2026. 52 weeks low was at CHF 454.6 on 03/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Holcim (HOLN.SW) traded up 5.03 % and now trades at CHF 66.88. Current market capitalisation for Holcim is CHF 37 bn. Holcim has a current price to earnings ratio of 18.16. Holcim reported strong quarterly results, prompting a modest rise in its shares. The company’s performance was highlighted as a positive contributor to the broader market, alongside other industrial names such as Sodexo. Meanwhile, market observers noted that Moody’s maintained France’s credit rating at Aa3, citing a diversified economy and robust public institutions, though political instability kept the outlook negative. Global equity indices showed limited movement, with European markets opening with small gains despite persistent oil price pressures. In the United States, the focus remained on forthcoming central‑bank decisions, with expectations of holding current policy rates. Currency markets reflected a slight weakening of the euro and a marginal strengthening of the dollar, while bond yields edged higher but stayed below key thresholds. Overall, the day was characterized by cautious optimism in corporate earnings, tempered by lingering geopolitical and economic uncertainties.

  • Sika (SIKA.SW) traded down -2.33 % and now trades at CHF 176.2. Current market capitalisation for Sika is CHF 28.9 bn. Current price/earnings ratio for Sika is 27.85. Sika AG announced the acquisition of Duproof, a Dubai‑based manufacturer of bitumen membrane solutions. The deal is intended to broaden Sika’s product range for large‑scale construction projects in the Gulf region and to strengthen its local production and distribution network in the United Arab Emirates. By integrating Duproof’s expertise into its existing supply chain, Sika aims to improve regional delivery capabilities and create cross‑selling opportunities with its established customer base. The acquisition is positioned as a strategic move to reinforce the company’s competitive stance in the rapidly growing UAE construction market while supporting its broader objective of expanding its footprint across the Middle East.

  • Garmin (GRMN) traded down -0.56 % and now trades at USD 292.92. Current market capitalisation for Garmin is USD 56.7 bn. Garmin has a current price to earnings ratio of 30.48.

  • Swisscom (SCMN.SW) traded up 0.07 % and now trades at CHF 682. Current market capitalisation for Swisscom is CHF 35.5 bn. Current price/earnings ratio for Swisscom is 26.95.

  • Galderma (GALD.SW) traded up 2.33 % and now trades at CHF 190.9. Galderma has a market capitalisation of CHF 44.6 bn. Current price/earnings ratio for Galderma is 78.21. Galderma Group AG continues to reinforce its position in the injectable aesthetics market, building on a stable portfolio that includes neuromodulators and dermal fillers. Recent sales figures demonstrate sustained growth, reflecting the company’s established relationships with practitioners and the widespread use of its products. In parallel, the company is exploring new delivery technologies, such as microneedle systems, to enhance precision and patient experience. While competitors like AbbVie expand their own multimodal treatment frameworks, Galderma’s focus remains on integrating proven ingredients with rigorous clinical data and regulatory compliance. The firm’s strategy emphasizes reliable dosing, safe application, and repeatable treatment processes, aiming to maintain its competitive advantage in a market that values both product efficacy and professional integration.

About Lonza

The Lonza Group AG is a Swiss-based company that specializes in partnership with the pharmaceutical, biotech, and nutrition industries, developing, manufacturing, and commercializing medical treatments and technologies to address a range of diseases.